An interventional study of vNOTES adnexectomy and Laparoscopic adnexectomy in Natural Orifice Endoscopic Surgery, Disease, Adnexal and Laparoscopic Surgery, sponsored by Imelda Hospital, Bonheiden. Completed at 1 site in Belgium. Open to female participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-06-11.
Sponsored by Imelda Hospital, Bonheiden · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Objective: To compare vNOTES (vaginal Natural Orifice Transluminal Endoscopic Surgery) and established laparoscopic removal of benign adnexal masses Study design: Randomized controlled/single center/single-blinded/parallel-group/non-inferiority/efficacy trial.
Study population: Women aged 18 to 70 years with symptomatic or persistent benign adnexal masses detected by clinical examination and ultrasound.
Randomization: Women will be randomly allocated to undergo one of two techniques for removal of the benign adnexal mass immediately before surgery by using a computer generated randomization list. The investigators will use stratified randomization according to the cyst diameter.
Intervention: Women will be treated by a surgeon who is not blinded to the treatment allocation and who is equally skilled in performing both techniques. In the intervention group a vNOTES technique will be used.
Control: In the control group surgery will be done by a classical laparoscopic technique.
Participants, nursing staff and outcome assessors will be blinded.
Main study parameters/endpoints:
Primary outcomes: successful removal of a benign adnexal mass without spill. Secondary outcomes: the proportion of women discharged the same day based on their own preference; postoperative pain scores using a VAS (Visual Analogue Scale) measured between day 1 till 7 by the participating women following surgery and the total amount of analgesics used as described in the standardized pain treatment protocol between day 1 till 7; postoperative infection defined by lower abdominal pain with fever > 38°C and positive clinical signs or laboratory findings; per- or postoperative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery; duration of the surgical procedure; incidence and intensity of dyspareunia recorded by the participants at 3 and 6 months by self-reporting using a simple questionnaire and VAS scale; sexual wellbeing recorded by the participants at 3 and 6 months by SSFS (Short Sexual Functioning Scale); direct costs associated up to 6 weeks after the surgical intervention with both procedures.
The primary research questions of this IDEAL stage 2b efficacy trial are as follows: is a vNOTES adnexectomy at least as effective compared to the standard transabdominal laparoscopic approach (LSC) for removing a benign adnexal mass without spill? (non-inferiority design)
Secondary research questions are:
TRIAL DESIGN 2.1. Design A single center, single-blinded, parallel group randomized, non-inferiority efficacy trial.
2.2. Simple pilot randomized trial: minimal extra workload 2.3. Time schedule Based upon the mean number of laparoscopic adnexectomies performed annually at the department of Obstetrics and Gynecology of the participating center (36) the investigators estimate that the duration of recruitment will be 21 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2.5 years.
2.4. Participating center Department of Obstetrics and Gynecology Imeldahospital Imeldalaan 9 2820 Bonheiden Belgium
3.2. Determining eligibility All women aged 18 to 70 years regardless of parity presenting with a symptomatic or asymptomatic persistent benign adnexal mass on clinical examination who provide consent to participation are eligible in the NOTABLE trial based on the findings of the ultrasound findings and will be randomized before the procedure.
3.3. Randomization If the woman is eligible for the NOTABLE trial, the trial secretary will obtain a randomized allocation the day before surgery. This will be done using a randomization list generated by a free computer software program offered by Research Randomizer (https://www.randomizer.org). The random sequence generation will be concealed using sequentially numbered opaque sealed envelopes. The envelope will be opened by the nurse assistant on the day before the surgical intervention for logistic reasons. The investigators will use stratified randomization in this small pilot RCT (randomized controlled trial) according to the cyst diameter.
3.4. Patients with strong preference for treatment A minority of women will express a clear preference for one of both treatments (e.g. strong desire to have no scar) and for this reason will not wish to be randomized between surgical treatments. To investigate how outcomes vary by choice, these women could be followed up in exactly the same way as for those women randomized into the NOTABLE trial. A formal non-randomized follow-up of these women will not be done for simple logistical reasons.
3.5. Stratification of randomization A blocked randomization procedure will be used to avoid chance imbalances for the parameter 'cyst diameter'.
To avoid any possibility of foreknowledge, the randomized allocation will not be given until all eligibility and stratification data have been given.
4.1.1 vNOTES adnexectomy This is the surgical procedure done in the intervention arm of the NOTABLE trial.
4.1.2 LSC adnexectomy This is the surgical procedure done in the control arm of the NOTABLE trial. 5. FOLLOW-UP AND OUTCOME MEASURES 5.1. Clinical assessments 5.1.1 Format PROMs will be collected using a postal questionnaire, which will include a combination of disease specific and generic measurement instruments.
The postal questionnaires will be sent from the NOTABLE Trial Office with postage paid envelopes two weeks before the due date. Reminders will be sent to the participants if the questionnaire is not returned within one week of the due date and attempts will be made to contact the women by phone if the questionnaire is not returned by two weeks after the due date.
5.1.2 Timing of assessments The primary outcome will be measured clinically at the end of the surgical procedure. In addition patient reported outcome measures (PROMs) will take place the evening of the surgical intervention (return home), during the first postoperative week (pain by Visual Analogue (VAS)scores and analgetic drugs) and at 3 and 6 months (dyspareunia/ sexual well being/ health related quality of life). Clinical physician assessment will take place the evening of the surgical intervention (return home) and during the first six weeks following surgery (pelvic infection, surgical complications, hospital readmission rate).
5.2. Primary clinical outcome measure The proportion of women successfully treated by removing the adnexal mass without spill, using a dichotomous outcome measure, will be used as a measure of efficacy.
5.3. Secondary clinical outcome measures
The following secondary outcomes will be measured:
5.4. Health economic outcomes The direct and indirect costs of both techniques up to 6 weeks after the surgical intervention will be calculated.
6.2. Projected accrual and attrition rates It is anticipated that recruitment of participants will take two years. Based upon the mean number of laparoscopic adnexectomies performed annually at the department of Obstetrics and Gynecology of the participating center (36) the investigators estimate that the duration of recruitment will be 21 months. Based upon the follow up (6 months) and the period of analysis/reporting (3 months) the total study period will be 2.5 years. First publication will be possible within four years of trial commencement.
Imelda Hospital, Bonheiden is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaginal Natural Orifice Transluminal Endoscopic Surgery
Procedure: vNOTES adnexectomy
Laparoscopic adnexectomy
Procedure: Laparoscopic adnexectomy
Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
Surgical removal of one or both adnexa by transabdominal laparoscopy
Successful removal of adnexal mass without spill
The proportion of women successfully treated by removing the adnexal mass without spill, using a dichotomous outcome measure, will be used as a measure of efficacy.
Time frame: Intraoperative
Discharge from the hospital the day of the surgical intervention
The proportion of women discharged the same day based on their own preference, as a dichotomous outcome. The decision to discharge or to admit to hospital for the night will be based solely on the choice of the woman to return home the same day or stay overnight.
Time frame: Dichotomous outcome measured on the day of the surgical intervention
Postoperative pain scores
Postoperative pain scores, as an ordinal outcome, measured using a VAS scale twice daily from day 1 till 7 self-reported by the participating women
Time frame: The first week after the surgical intervention
The use of analgesics for postoperative pain
Postoperative pain defined by the total amount of analgesics used as described in the standardized pain treatment protocol, as a continuous outcome.
Time frame: The first week after the surgical intervention
Postoperative infection
Postoperative infection defined by lower abdominal pain with fever \> 38°C and positive clinical signs or laboratory findings, detected during the first six weeks of surgery, as a dichotomous outcome.
Time frame: The first six weeks after the surgical intervention
Complications
Per- or postoperative complications according to the Clavien- Dindo classification detected during the first six weeks of surgery, as a dichotomous outcome
Time frame: The first six weeks after the surgical intervention
Hospital readmission
The proportion of women readmitted to hospital within six weeks of surgery, as a dichotomous outcome
Time frame: The first six weeks after the surgical intervention
Pain during sexual intercourse
Incidence and intensity of dyspareunia recorded by the participants at 3 and 6 months by self-reporting using a simple questionnaire and VAS scale, as a dichotomous and ordinal outcome
Time frame: At baseline, 3 months and 6 months after the surgical intervention
Sexual well being
Sexual wellbeing at baseline, at 3 and 6 months by self-reporting using the SSFS (Short Sexual Function Scale).
Time frame: At baseline, 3 months and 6 months after the surgical intervention
Duration of the surgical intervention
Duration of surgery measured as the time in minutes from the insertion of the bladder catheter to the end of vaginal/abdominal wound closure, as a continuous outcome
Time frame: Intraoperative
Direct and indirect costs
Calculating the comparative direct costs of both techniques up to 6 weeks after the surgical intervention
Time frame: Up to 6 weeks postoperative
Health-related quality of life
Health-related quality of life, at baseline, at 3 and 6 months by self-reporting the EQ-5D-3L questionnaire
Time frame: At baseline, at 3 months and 6 months after the surgical intervention
Plan to share: No — Interim analyses of major endpoints will be supplied, in strict confidence, to an independent Data Monitoring and Ethics Committee (DMEC) along with updates on results of other related studies, and any other analyses that the DMEC may request.
Ran from Feb 2016 to primary completion in Apr 2020, 50 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adnexal Diseases
Imelda Hospital, Bonheiden